Qualigen Therapeutics Inc (QLGN): Price and Financial Metrics
QLGN Price/Volume Stats
| Current price | $0.32 | 52-week high | $1.26 |
| Prev. close | $0.33 | 52-week low | $0.29 |
| Day low | $0.31 | Volume | 36,200 |
| Day high | $0.33 | Avg. volume | 62,756 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.73 | Market Cap | 2.02M |
QLGN Stock Price Chart Interactive Chart >
Qualigen Therapeutics Inc (QLGN) Company Bio
Qualigen Therapeutics Inc operates as a biotech company. The Company develops and discovers novel therapeutic products for the treatment of cancer and infectious diseases. Qualigen Therapeutics serves customers in the State of California.
Latest QLGN News From Around the Web
Below are the latest news stories about QUALIGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate QLGN as an investment opportunity.
QLGN: Dosing Begins in Phase 1 Trial of QN-302…By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Dosing Begins in Phase 1 Trial of QN-302 On November 7, 2023, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced that the first three patients have begun dosing in the Phase 1a clinical trial of QN-302. This is a multicenter, open label, dose escalation, and dose expansion trial evaluating the safety, |
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024Expect to select lead Pan-RAS inhibitor candidate for IND enabling studies in first quarter of 2024 CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics co |
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsCARLSBAD, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumo |
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerPoster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breas |
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1 Two posters include data on potential clinical biomarkers and transcriptomic data associated with QN-302’s mechanism of action CARLSBAD, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces t |
QLGN Price Returns
| 1-mo | -13.56% |
| 3-mo | -37.86% |
| 6-mo | -62.35% |
| 1-year | -68.16% |
| 3-year | -98.24% |
| 5-year | -99.86% |
| YTD | -41.82% |
| 2023 | -57.33% |
| 2022 | -87.95% |
| 2021 | -64.45% |
| 2020 | -28.72% |
| 2019 | -71.85% |
Loading social stream, please wait...